Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.

Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Yu Shen(University of Florida), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), Mary E. Westerman(The University of Texas MD Anderson Cancer Center), Nathan A. Brooks(Eli Lilly (United States)), Wei Qiao(The University of Texas MD Anderson Cancer Center), Andrea Kokorovic(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
The Journal of Urology
May 22, 2023
10.1097/ju.0000000000003553
Cited by 0

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
|Nature|2020|404